Iterum Therapeutics plc Investors: Company studied by


LOS ANGELES, Aug 11, 2021 (GLOBE NEWSWIRE) – The Portnoy law firm informs investors of Iterum Therapeutics plc (“Iterum” or the “Company”) (NASDAQ: ITRM) that the company has opened an investigation into possible securities fraud and may file a class action on behalf of the investors.

Investors are encouraged to contact a lawyer Lesley F. Portnoy, by phone 310-692-8883 or E-mail: [email protected], to discuss their legal rights, or Click here join the case via The Portnoy law firm can provide further case assessment and discuss options for investors to pursue claims to recover their losses.

It is alleged in this lawsuit that Iterum throughout the Class Period made misleading and / or false statements and / or failed to disclose that: (1) Sulopenem’s New Drug Application (“NDA”) lacked sufficient data to support the approval of treatment for adult women with uncomplicated urinary tract infections (“UTI”) caused by susceptible microorganisms designated, proven or strongly suspected to be non-sensitive to a quinolone; (2) it was unlikely that the US Food and Drug Administration (“FDA”) would approve sulopenem NDA in its current form, accordingly; (3) Iterum downplayed the severity of the problems and shortcomings associated with the NDA of sulopenem; and (4) Iterum’s public statements were materially false and misleading at all relevant times, accordingly. This lawsuit claims that investors suffered damage when the real details entered the market.

Please visit our website to view more information and submit your transaction information.

The Portnoy law firm represents investors in the pursuit of claims arising from corporate wrongdoing. The company’s founding partner has recovered more than $ 5.5 billion for aggrieved investors. Lawyer advertising. Past results do not guarantee similar results.

Lesley F. Portnoy, Esq.
CA and NY bar admitted
[email protected]

Lawyer Advertising


Comments are closed.